Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapt Therapeutics Inc (NQ: RAPT )

19.18 -0.05 (-0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 146,442
Open 19.34
Bid (Size) 19.18 (1)
Ask (Size) 22.00 (1)
Prev. Close 19.23
Today's Range 18.68 - 20.23
52wk Range 9.855 - 40.74
Shares Outstanding 29,644,130
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So
 
Via Benzinga
What 4 Analyst Ratings Have To Say About RAPT Therapeutics
Analysts have provided the following ratings for RAPT Therapeutics (NASDAQ:RAPT) within the last quarter: 
Via Benzinga

Performance

YTD
-50.46%
-50.46%
1 Month
+23.98%
+23.98%
3 Month
-18.49%
-18.49%
6 Month
-51.42%
-51.42%
1 Year
-39.09%
-39.09%

More News

Read More
Starbucks And 2 Other Stocks Insiders Are Buying
Via Benzinga
Recap: RAPT Therapeutics Q1 Earnings
Via Benzinga
RAPT Therapeutics's Return On Capital Employed Insights
Via Benzinga
RAPT Therapeutics: Q4 Earnings Insights
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
65 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Via Benzinga
Topics Retirement
Exposures Pension
60 Biggest Movers From Yesterday
Via Benzinga
How Good Are RAPT Therapeutics's Earnings? | Return On Capital Employed
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2021
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Via Benzinga
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
RAPT Therapeutics Raises $125M Via Equity At 6% Discount
Via Benzinga
Stocks That Hit 52-Week Highs On Tuesday
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Via Benzinga
60 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.